Brit J Heamatol: Statins and epoxy 2 inhibitors improve survival in patients with diffuse large B cell lymphoma

Preclinical data show that statins, metformin and epoxy-2 (COX-2) inhibitors have the potential to fight lymphomaIn a recent study published in the journal British Journal of Haematology, researchers reviewed the population of all transsexual lymphoma patients diagnosed with diffuse large B-cell lymphoma (DLBCL) or rituximatherapy in Ontario, Canada, between 2005 and 2015 in Ontario, Canadaresearchers used a management database to assess the effects of drug exposure on lymphoma survival before chemotherapy immunotherapyAfter adjusting sociodemographic factors and comorbidities, the researchers used Cox regression analysis to assess the relationship between drug exposure and survival4913 patients were treated (median age is 75 years old and 51% male) and 52.2% of patients died within one year of the start of treatment (67%) dLBCLIn the year prior to the start of treatment, 45.7% of patients took statins, 16.3% of patients took metformin and 25.0% took COX2 inhibitorsAfter adjusting the mixed factors, starting statins and COX 2 inhibitor treatmentpriors prior to chemotherapy has survival benefits: statin systinic drugs for 30 days (risk ratio of 0.97, 95% confidence interval of 0.96-0.98), 180 days (HR 0.84, 95% CI 0.80-0.89) and 365 days (HR011, 95% CI is 0.63-0.79), and COX 2 inhibitors are treated for 30 days (0.95 HR, 0.95-0.98 for 95% CI), 180 days (0.76, 95% CI 0.66-0.86) and 365 days (0.57 HR, 95% CI 0.43-0.74)There was no significant effect on metformin, the use of statins and COX-2 inhibitors had dose-related survival benefits for patients prior to immunotherapy in newly diagnosed DLBCL patients